FDA
-
-
-
-
-
-
-
Acasti to Present at the Life Sciences Investor Forum
-
-
-
-
-
-
-
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
-
-
-
-
-
-
-
Acasti to Participate in the H.C. Wainwright Global Investment Conference
-
-
-
-
-
-
-
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023
-
-
-
-
-
-
-
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND
-
-
-
-
-
-
-
Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023
-
-
-
-
-
-
-
Acasti Pharma (ACST) Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

